FASLG and breast carcinoma: In addition, serum levels of FasL have been shown to be elevated after chemotherapy compared to levels before chemotherapy in stage II and III breast cancer patients, indicating FasL as a possible marker for evaluating treatment efficacy in breast cancer [50].